Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28142917 | 0.94 | KEAP1 (0.57) | KEAP1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL696834 | 0.86 | KEAP1 (0.52) | KEAP1SMN1; SMN2KDM4ELMNAHPGD | |
| Hydrochloric Acid SCHEMBL165528 | 0.84 | KEAP1 (0.50) | KEAP1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL721355 | 0.82 | PAOX (0.64) | KEAP1SMN1; SMN2KDM4ELMNAHPGD | |
| Hydrochloric Acid SCHEMBL2488967 | 0.80 | PAOX (0.62) | KEAP1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL8310330 | 0.79 | KEAP1 (0.67) | KEAP1SMN1; SMN2KDM4ELMNAHPGD | |
| Methylamine SCHEMBL7979606 | 0.79 | SMN1; SMN2 (0.55) | KEAP1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL1385342 | 0.78 | HPGD (0.58) | KEAP1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL46511 | 0.78 | HPGD (0.58) | KEAP1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL12428257 | 0.78 | HPGD (0.58) | KEAP1SMN1; SMN2KDM4ELMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11565994-B2 | Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACS) | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | disclosed |
| US-20210009511-A1 | INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS) | THE JOHNS HOPKINS UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| EP-3267794-B1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2020-09-09 | — | — | EP | disclosed |
| WO-2020160174-A1 | USES OF COMPOUNDS HAVING ANTI-HSV-1 ACTIVITY | UNIVERSITA DEGLI STUDI DI PADOVA (IT) | 2020-08-06 | — | — | WO | disclosed |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| CN-110914263-A | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors | 格兰马克药品股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3619209-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-06-27 | — | — | US | disclosed |
| EP-3154966-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | US HEALTH (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20170029366-A1 | INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS) | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-02 | — | — | US | disclosed |
| EP-3114109-A1 | INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS) | The Johns Hopkins University (US) | 2017-01-11 | — | — | EP | disclosed |
| US-9439968-B2 | Amine-containing lipidoids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2015134973-A1 | INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS) | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2011146182-A1 | FUNGICIDAL OXIMES AND HYDRAZONES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| EP-1836188-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006070198-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| US-4173634-A | Basically-substituted tricyclic pyrazoles useful as antiinflammatory agents | E. R. SQUIBB & SONS, INC. (US) | 1979-11-06 | — | — | US | disclosed |
| US-4004007-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | KEAP1 896/4885SMN1; SMN2 4280/4885KDM4E 1031/4885 |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK1, CDK3, CDK13 | KEAP1 1953/4885SMN1; SMN2 3277/4885KDM4E 990/4885 |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | KEAP1 266/4885SMN1; SMN2 3077/4885KDM4E 4117/4885 |
| US-11565994-B2 | Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACS) | KDM1B, KDM2A, EHMT2 | KEAP1 287/4885SMN1; SMN2 231/4885KDM4E 21/4885 |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | KEAP1 898/4885SMN1; SMN2 4317/4885KDM4E 1015/4885 |
| US-20210009511-A1 | INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS) | KDM1B, KDM2A, EHMT2 | KEAP1 287/4885SMN1; SMN2 231/4885KDM4E 21/4885 |
| US-20170029366-A1 | INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS) | KDM1B, KDM2A, EHMT2 | KEAP1 287/4885SMN1; SMN2 231/4885KDM4E 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.